Aprea Therapeutics (APRE) Price & Analysis

Compare

496 Followers

APRE Stock Chart & Stats

$0.61

-$0.03(-0.72%)

At close: Jan 08 4:00 PM EST

$0.61

-$0.03(-0.72%)

Day’s Range― - ―

52-Week Range$0.55 - $3.72

Previous CloseN/A

Volume2.88K

Average Volume (3M)55.77K

Market Cap

$4.29M

Enterprise Value-$9.46M

Total Cash (Recent Filing)$13.72M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.90

Next Earnings

Mar 26, 2026

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.47

Shares Outstanding6,993,838

10 Day Avg. Volume84,633

30 Day Avg. Volume55,770

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.94

Price to Sales (P/S)12.06

P/FCF Ratio-1.34

Enterprise Value/Market Cap-2.20

Enterprise Value/Revenue-19.37

Enterprise Value/Gross Profit1.51

Enterprise Value/Ebitda0.69

Forecast

1Y Price Target

$5.33

Price Target Upside773.77% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Biomarker-targeted DevelopmentTargeting biomarker-defined populations such as HPV-positive cancers could concentrate development efforts, potentially enabling a more efficient regulatory path and clearer commercial positioning.

Clinical DifferentiationSuperior clinical performance of APR-1051 versus other WEE1 inhibitors could establish a best-in-class position, driving market share given the winner-takes-most dynamics in the class.

Safety And Dosing ProfileA clean safety profile that supports continuous daily dosing and enables dose escalation may allow higher therapeutic exposure and distinguish the candidate from intermittent-dosing competitors.

Bears Say

Analyst Valuation ImpactAnalyst price target reductions tied to fundraising-related dilution can weaken investor confidence and weigh on the company's valuation despite encouraging trial signals.

Clinical Program PausePausing the ATRN-119 monotherapy study to conserve cash introduces execution risk and could delay key data readouts and planned combination strategies.

Equity DilutionAn equity financing that raised capital has put downward pressure on the stock by increasing dilution concerns and offsetting positive sentiment around clinical progress.

Aprea Therapeutics News

Aprea announces expansions of its global intellectual property estate

Aprea Therapeutics (APRE) announced significant recent expansions of its global intellectual property estate supporting its DDR-focused oncology pipeline....

2d ago

APRE

Aprea Therapeutics price target lowered to $7 from $11 at Wedbush

Wedbush lowered the firm’s price target on Aprea Therapeutics (APRE) to $7 from $11 and keeps an Outperform...

4d ago

APRE

Aprea Therapeutics appoints Kennedy as Chief Medical Advisor

Aprea Therapeutics (APRE) announced the appointment of Eugene Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy joins Aprea...

10d ago

APRE

Aprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Aprea Therapeutics (APRE) to $4 from $5...

16d ago

APRE

Aprea Therapeutics prices 6.29M shares at 89c in private placement

Aprea Therapeutics (APRE) entered into a securities purchase agreement with new and existing healthcare focused institutional investors and...

16d ago

APRE

Aprea Therapeutics announces early PoC data in ACESOT-1051 trial

Aprea Therapeutics (APRE) announced the first unconfirmed partial response observed in a patient enrolled in its ongoing Phase...

16d ago

APRE

APR-1051’s Emerging Best-in-Class WEE1 Profile Underpins Buy Rating on Aprea Therapeutics

Aprea Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

4d ago

APRE

Aprea Therapeutics Announces Financing and Early Trial Response

The latest update is out from Aprea Therapeutics ( ($APRE) ). On January 28, 2026, Aprea Therapeutics entered...

16d ago

APRE

Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook

Aprea Therapeutics ( ($APRE) ) has issued an update. On January 9, 2026, Aprea Therapeutics updated its corporate...

1M ago

APRE

Aprea Therapeutics files to sell 5.5M shares of common stock for holders

16:15 EST Aprea Therapeutics (APRE) files to sell 5.5M shares of common stock for holders Published first on...

2M ago

APRE

Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics, reducing the price target to...

2M ago

APRE

Aprea Therapeutics price target lowered to $5 from $20 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Aprea Therapeutics (APRE) to $5 from $20 and keeps a...

2M ago

APRE

Aprea Therapeutics CEO issues letter to shareholders

Aprea Therapeutics (APRE) issued the following letter to shareholders from Chief Executive Officer, Oren Gilad. The letter highlights...

2M ago

APRE

Aprea Therapeutics Secures $3.1M in Private Placement

Aprea Therapeutics ( ($APRE) ) just unveiled an update. On December 8, 2025, Aprea Therapeutics entered into a...

2M ago

APRE

APRE FAQ

What was Aprea Therapeutics Inc’s price range in the past 12 months?

Aprea Therapeutics Inc lowest stock price was $0.55 and its highest was $3.71 in the past 12 months.

What is Aprea Therapeutics Inc’s market cap?

Aprea Therapeutics Inc’s market cap is $4.29M.

When is Aprea Therapeutics Inc’s upcoming earnings report date?

Aprea Therapeutics Inc’s upcoming earnings report date is Mar 26, 2026 which is in 40 days.

How were Aprea Therapeutics Inc’s earnings last quarter?

Aprea Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.13.

Is Aprea Therapeutics Inc overvalued?

According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aprea Therapeutics Inc pay dividends?

Aprea Therapeutics Inc does not currently pay dividends.

What is Aprea Therapeutics Inc’s EPS estimate?

Aprea Therapeutics Inc’s EPS estimate is -0.39.

How many shares outstanding does Aprea Therapeutics Inc have?

Aprea Therapeutics Inc has 6,993,838 shares outstanding.

What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?

Aprea Therapeutics Inc reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -4.545%.

Which hedge fund is a major shareholder of Aprea Therapeutics Inc?

Currently, no hedge funds are holding shares in APRE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Aprea Therapeutics (APRE) Earnings & Revenues

Historic Earnings Reports

APRE Stock 12 Month Forecast

Average Price Target

$5.33

▲(773.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.75,1.2307692307692308,1.7115384615384617,2.1923076923076925,2.6730769230769234,3.1538461538461537,3.6346153846153846,4.115384615384615,4.596153846153847,5.076923076923077,5.5576923076923075,6.038461538461538,6.519230769230769,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.75,1.1023076923076922,1.4546153846153846,1.806923076923077,2.1592307692307693,2.5115384615384615,2.863846153846154,3.2161538461538464,3.5684615384615386,3.920769230769231,4.273076923076923,4.625384615384616,4.977692307692308,{"y":5.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.75,1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.533,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.853,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >